Most founders read NICE Evidence Standard 18 as a compliance document. They’re wrong. Standard 18 is a pricing document — and right now, in April 2026, the reference points behind it have just shifted in a way that changes the maximum defensible price for every digital health technology entering the NHS market this year.
On 8 April 2026 NICE confirmed it would lift its cost-effectiveness threshold from £20,000–£30,000 per QALY to £25,000–£35,000 per QALY. This is the first material movement in NICE’s reference threshold since 1999. For DHT founders modelling cost-effectiveness today, this is not a footnote. It is a 25% expansion of the price headroom you can defend to a NICE committee — and the founders who build their economic case around the new reference point will price differently from the founders who don’t.
This post argues that Standard 18 — the highest analytical bar in the NICE Evidence Standards Framework — should be approached as a pricing instrument from day one, not a checkbox at the end of an evidence programme. Doing so changes the model you build, the data you collect, and the price you negotiate.
The threshold just moved. Most economic models haven't yet
NICE’s cost-effectiveness threshold isn’t a number. It’s a price ceiling.
Every economic model submitted under Standard 18 ends in the same calculation: an incremental cost-effectiveness ratio (ICER) — the cost of buying one additional quality-adjusted life year (QALY) with this technology versus current practice. NICE then asks one question: is the ICER below the threshold? If yes, the technology represents value for money on the NHS’s terms. If no, it doesn’t — and the price has to come down, or the evidence has to come up.
From April 2026, that ceiling is rising. The new threshold applies to all new technology appraisals and to appraisals already in flight once the regulatory mechanics are in place. NICE itself estimates the change will allow it to recommend an additional 3–5 medicines or indications per year. For DHTs, the directional implication is the same: at any given level of clinical benefit, the price the NHS can defensibly pay is higher.
The corollary cuts the other way too. Founders pricing against the old £30,000 ceiling are now potentially leaving money on the table. Those who haven’t reread their economic model since the NICE announcement are running a model with an outdated reference case.
Standard 18 is a pricing instrument. Use it that way.
There is a tidy way to read Standard 18 — as the cost-utility analysis (CUA) NICE expects from any DHT representing higher financial risk to the NHS. There is a sharper way to read it.
If your CUA reports an ICER of £18,000 per QALY at your current list price, that is not just a passing grade. It is information. It tells you that, holding clinical benefit constant, you could raise list price meaningfully and still sit comfortably below the new £25,000 lower bound. If your ICER is £42,000 per QALY, the same logic runs in the other direction: your price is wrong relative to your evidence, and either the price needs to come down or the clinical benefit case needs strengthening before you go anywhere near a NICE committee.
This is why the CUA should be built early in the evidence programme — before the price has been set, before procurement conversations begin, ideally before the pivotal trial protocol is locked. The model tells you what the data needs to look like to defend a particular price point. Run the logic backwards: pick a defensible target price, model the clinical benefit needed to clear the threshold at that price, and design the evidence programme to deliver it. Most DHT founders do this in the wrong order — set price commercially, then commission a retrospective economic model, then discover the numbers don’t reconcile.
The companies that get this right look like pharmaceutical companies in their second appraisal cycle — economic logic and pricing logic running in parallel from early development, with the model maintained as a living document, not a one-shot submission artefact.
The methodological gaps DHT founders need to navigate
DHT economic evaluation is harder than the textbook version, and Standard 18 makes no allowance for that. A handful of recurring failure modes deserve explicit attention.
Utility data — collected, not assumed
The QALY rests on utility weights between 0 (death) and 1 (perfect health). NICE’s reference case uses the EQ-5D instrument. A persistent failure across DHT submissions is reaching the modelling stage without primary EQ-5D data — leaving the team to map utilities from condition-specific instruments or borrow values from published populations that don’t match the trial cohort. NICE’s external assessment groups will spot this. Build EQ-5D collection into the trial protocols supporting Standards 14 and 15, not as an afterthought.
Pathway substitution effects
Most DHTs change clinical pathways rather than adding to them — an AI triage tool reroutes which patients reach a consultant; a digital therapeutic substitutes for a course of CBT; a remote monitoring platform reduces hospital admissions but increases primary care contacts. Pharmaceutical-style cost-utility models, structured around disease progression, often misrepresent these effects. The economic model should reflect the pathway changes captured in Standard 12 and the differential performance described in Standard 15 — both for credibility and for accuracy.
Discount rates, applied consistently
NICE requires both costs and outcomes to be discounted at 3.5% per annum for analyses extending beyond one year. Inconsistent discounting — applying the rate to costs but not outcomes, or to one but not the other — is a tell-tale of analytical inexperience and one of the fastest ways to lose credibility with a committee. The NICE methods manual (PMG36) is unambiguous on this point. There is no excuse to get it wrong.
Time horizons that match the technology
DHTs in chronic disease management deliver value over years, not weeks. Modelling a long-term condition over a 12-month time horizon understates lifetime benefit and produces a misleadingly poor ICER. The horizon should run as long as it takes to capture all clinically and economically relevant differences between intervention and comparator — for a Type 2 diabetes management platform, that may mean a lifetime model, not a one-year analysis.
What this means for founders pricing in 2026
Three implications follow from reading Standard 18 as a pricing instrument under the new threshold.
First, every DHT economic model dated before April 2026 should be revisited. If the base case ICER sits in the £25,000–£35,000 band, the technology that was previously borderline is now squarely cost-effective — and the price has room to move. If the ICER sits above £35,000, the strategic answer hasn’t changed but the evidence required to defend it has. Either way, the model needs to be re-run against the new reference case.
Second, founders preparing for NICE’s Early Value Assessment programme — which has now produced more than 21 published assessments since launch — should treat the cost-effectiveness analysis as a strategic asset, not an afterthought. EVAs sit upstream of full HTA, but the economic case made in an EVA shapes the conditions under which evidence generation proceeds. A weak economic model produces unfavourable evidence-generation requirements; a strong one produces a more navigable path to full recommendation.
Third, pricing strategy needs to coexist with international reality. The UK is not the only market with a formal DHT reimbursement pathway. Germany’s DiGA framework has now reimbursed over 56 listed products, with median launch prices around €514 per three-month prescription typically negotiated down by roughly 50% post-listing. UK NICE pricing decisions inform what European payers will accept; international scale planning should treat the NICE ICER as one of several reference points, not the only one.
The so what?
Standard 18 is the most analytically demanding standard in the NICE Evidence Standards Framework. It is also the most strategically useful one. Read as a pricing document, the cost-utility analysis tells a founder what the NHS can defensibly pay for their technology at their current level of clinical evidence — and what the model needs to look like to support a higher price.
The threshold change in April 2026 is the first material expansion of the NHS price ceiling for new technologies in 27 years. The DHT founders who incorporate the new reference points into their economic models, run the logic from price target back to evidence requirement, and treat Standard 18 as a board-level pricing decision rather than a regulatory submission task — those are the ones whose products will be commercially defensible at scale.
If you’re building a DHT and you haven’t rerun your cost-utility analysis since the threshold change, that is the next thing to do. Healthonomix helps DHT companies build economic models tuned to NICE’s reference case and the new threshold logic. Get in touch.
